Trial · NCT03499873
Adverse events222
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 222
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Vertigo | Ear and labyrinth disorders | Nepafenac 0.3% Opthalmic Suspension | 0 | 175 | |
| other | Vertigo | Ear and labyrinth disorders | Ilevro 0.3% Opthalmic Suspension | 1 | 174 | |
| other | Vertigo | Ear and labyrinth disorders | Placebo (Vehicle) Opthalmic Suspension | 0 | 80 | |
| other | Altered visual depth perception | Eye disorders | Nepafenac 0.3% Opthalmic Suspension | 0 | 175 | |
| other | Altered visual depth perception | Eye disorders | Ilevro 0.3% Opthalmic Suspension | 0 | 174 | |
| other | Altered visual depth perception | Eye disorders | Placebo (Vehicle) Opthalmic Suspension | 1 | 80 | |
| other | Anterior chamber cell | Eye disorders | Nepafenac 0.3% Opthalmic Suspension | 0 | 175 | |
| other | Anterior chamber cell | Eye disorders | Ilevro 0.3% Opthalmic Suspension | 0 | 174 | |
| other | Anterior chamber cell | Eye disorders | Placebo (Vehicle) Opthalmic Suspension | 1 | 80 | |
| other | Anterior chamber disorder | Eye disorders | Nepafenac 0.3% Opthalmic Suspension | 1 | 175 | |
| other | Anterior chamber disorder | Eye disorders | Ilevro 0.3% Opthalmic Suspension | 0 | 174 | |
| other | Anterior chamber disorder | Eye disorders | Placebo (Vehicle) Opthalmic Suspension | 0 | 80 | |
| other | Anterior chamber fibrin | Eye disorders | Nepafenac 0.3% Opthalmic Suspension | 1 | 175 | |
| other | Anterior chamber fibrin | Eye disorders | Ilevro 0.3% Opthalmic Suspension | 0 | 174 | |
| other | Anterior chamber fibrin | Eye disorders | Placebo (Vehicle) Opthalmic Suspension | 0 | 80 | |
| other | Anterior chamber inflammation | Eye disorders | Nepafenac 0.3% Opthalmic Suspension | 4 | 175 | |
| other | Anterior chamber inflammation | Eye disorders | Ilevro 0.3% Opthalmic Suspension | 2 | 174 | |
| other | Anterior chamber inflammation | Eye disorders | Placebo (Vehicle) Opthalmic Suspension | 2 | 80 | |
| other | Blepharitis | Eye disorders | Nepafenac 0.3% Opthalmic Suspension | 1 | 175 | |
| other | Blepharitis | Eye disorders | Ilevro 0.3% Opthalmic Suspension | 0 | 174 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03499873/events